Show simple item record

dc.creatorIbáñez Sanz, Gemmaes_ES
dc.creatorDíez Villanueva, Annaes_ES
dc.creatorVilorio Marqués, Lauraes_ES
dc.creatorGracia, Estheres_ES
dc.creatorAragonés, Nuriaes_ES
dc.creatorOlmedo Requena, Rocíoes_ES
dc.creatorLlorca, Javieres_ES
dc.creatorVidán, Juanaes_ES
dc.creatorAmiano, Pilares_ES
dc.creatorNos, Pilares_ES
dc.creatorFernández Tardón, Guillermoes_ES
dc.creatorRada, Ricardoes_ES
dc.creatorChirlaque, María Doloreses_ES
dc.creatorGuinó, Elisabetes_ES
dc.creatorDávila Batista, Verónicaes_ES
dc.creatorCastaño Vinyals, Gemmaes_ES
dc.creatorPérez Gómez, Beatrizes_ES
dc.creatorMirón Pozo, Benitoes_ES
dc.creatorDierssen Sotos, Trinidades_ES
dc.creatorEtxeberria Andueza, Jaionees_ES
dc.creatorMolinuevo, Amaiaes_ES
dc.creatorÁlvarez Cuenllas, Begoñaes_ES
dc.creatorKogevinas, Manolises_ES
dc.creatorPollán, Marinaes_ES
dc.creatorMoreno, Víctores_ES
dc.date.accessioned2018-09-19T09:37:43Z
dc.date.available2018-09-19T09:37:43Z
dc.date.issued2018
dc.identifier.issn2045-2322 (Electronic)
dc.identifier.urihttps://hdl.handle.net/2454/30721
dc.description.abstractA safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28–0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47–1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62–0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.en
dc.description.sponsorshipThis work was supported by the ‘Acción Transversal del Cancer’, approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds –‘a way to build Europe’ (grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613, and PI15/00069). Support was also provided by the Fundación Marqués de Valdecilla (grant API 10/09); the Junta de Castilla y León (grant LE22A10–2); the Consejería de Salud of the Junta de Andalucía (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (grant AP 061/10); the Recercaixa (grant 2010ACUP 00310); the Regional Government of the Basque Country; the Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; the Fundación Científica Asociación Española Contra el Cáncer (AECC); the Catalan Government DURSI (grant 2014SGR647); the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat Catalana de Digestologia; and COST action BM1206 Eucolongene.en
dc.format.extent8 p.
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherSpringer Natureen
dc.relation.ispartofScientific Reports, (2018) 8:2040en
dc.rights© The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectColorectal canceren
dc.subjectGlucosamineen
dc.subjectChondroitin sulphateen
dc.titlePossible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain studyen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeArtículo / Artikuluaes
dc.contributor.departmentUniversidad Pública de Navarra. Departamento de Estadística e Investigación Operativaes_ES
dc.contributor.departmentNafarroako Unibertsitate Publikoa. Estatistika eta Ikerketa Operatiboa Sailaeu
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.rights.accessRightsAcceso abierto / Sarbide irekiaes
dc.identifier.doi10.1038/s41598-018-20349-6
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-018-20349-6
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.type.versionVersión publicada / Argitaratu den bertsioaes


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and your intended use is not permitted
by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder.
Except where otherwise noted, this item's license is described as © The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.